국내 육 가공품의 소비성향에 관한 연구

윤명헌,장경만,최일신 한국축산식품학회 2001 한국축산식품학회지 Vol.21 No.1

동맥관개존증과 그 치료 방법이 미숙아망막병증에 미치는 영향

윤명헌,백완기,문연성,Myung Hun Yoon,MD,Wan Ki Baek,MD,PhD,Yeon Sung Moon,MD,PhD 대한안과학회 2013 대한안과학회지 Vol.54 No.5

Purpose: This study investigated the influence of patent ductus arteriosus (PDA) and its treatment on incidence and progression of retinopathy of prematurity (ROP). Methods: The authors retrospectively reviewed the medical records of 408 infants who underwent screening examinations for ROP at the Neonatal Intensive Care Unit of our hospital. Results: The total incidence of ROP was 23.5% (96 out of 408) and the patients that needed treatment were 7.4% (30 out of 408). The mean birth weight and gestational age was 1406.1 grams and 30.67 weeks in patients without ROP, and 979.8 grams and 27.46 weeks in patients with ROP, respectively. In both total and very low birth weight (VLBW) patients, the incidence of ROP was higher in the PDA group than the non-PDA group, but the PDA group was an independent risk factor only in the VLBW group (p = 0.033). The incidence of threshold disease was not significantly different between the PDA and control groups (p = 0.757). There was no significant difference of incidence of ROP and threshold disease among the 3 treatment groups for PDA. Conclusions: In VLBW patients, the presence of PDA increased the risk of ROP and its progression, thus more attention is needed for PDA patients. However, there was no significant difference in ROP incidence and progression according to different PDA treatment methods.

당뇨병환자에서 유리체절제술 후 다초점 인공수정체의 지연성 혼탁

윤명헌,김세영,진희승 대한안과학회 2019 대한안과학회지 Vol.60 No.12

Purpose: We report a case of late opacity of an AT LISA intraocular lens after vitrectomy in a diabetic patient. Case summary: A 61-year-old man presented with blurring in the left eye. He had undergone bilateral phacoemulsification and intraocular lens implantation 6 years ago, and vitrectomy with SF6 gas tamponade in the left eye due to rhegmatogenous retinal detachment 3 years ago. The patient was diagnosed with pre-existing diabetes, hypertension, and coronary heart disease. Examination of the left eye showed round and centrally located whitish fine granular deposits on the surface of the intraocular lens, and zonular rupture from the 3 to 6 o’clock position. The intraocular lens in the right eye was clear. The corrected vision was 0.9 in the right eye and 0.5 in the left eye. The intraocular lens was explanted from the left eye together with the capsular bag, and was examined under light microscopy, histochemical analysis, and with scanning electron microscopy equipped with an energy dispersive X-ray spectroscopy detector with light element capabilities. Conclusions: This study was the first to report late postoperative opacity in the multifocal intraocular lens, AT LISA 809M. The possibility of intraocular lens opacity in patients with underlying disease or in those undergoing vitrectomy should be explained prior to corrective procedures. 목적: 당뇨병환자에서 유리체절제술 후 AT LISA 인공수정체의 지연성 혼탁을 경험하여 보고하고자 한다. 증례요약: 61세 남자 환자가 좌안 흐림을 주소로 내원하였다. 그는 6년 전 양안 수정체초음파유화술과 인공수정체삽입술을 받았고, 3년 전에 좌안의 열공망막박리로 SF6 가스 안내 주입술과 유리체절제술을 받았다. 환자는 기저질환으로 당뇨병, 고혈압 및 심장 관상동맥질환이 있었다. 좌안 세극등현미경검사상 인공수정체 표면 중앙에 둥글고 흰색의 과립성 침착이 관찰되었고, 3시에서 6시 방향에서 섬모체소대 파열이 관찰되었다. 우안의 인공수정체는 깨끗하였다. 교정시력은 우안 0.9, 좌안 0.5였다. 좌안의 인공수정체는 수정체낭과 함께 제거하였고 광학현미경, 조직화학 분석, 주사전자현미경 분석을 시행하였다. 결론: 본 연구는 다초점 인공수정체 AT LISA 809M에서 수술 후 지연성 인공수정체 혼탁에 관한 최초의 보고로 기저질환이 있는 환자나 유리체절제술 시행 예정인 환자에서 인공수정체 혼탁의 발생 가능성을 적절하게 설명하여야 할 것이다.

유리체내 베바시주맙과 라니비주맙 주입술이 전신 순환에 미치는 영향

윤명헌(Myung Hun Yoon),김영준(Young Jun Kim),이소영(So Young Lee),이강원(Kang Won Lee),진희승(Hee Seung Chin) 대한안과학회 2016 대한안과학회지 Vol.57 No.3

목적: 유리체내 항혈관내피성장인자 주입술 전후로 항혈관내피성장인자와 혈관내피성장인자의 혈중 농도가 어떻게 변화하는지 알아보았다. 대상과 방법: 총 28명의 망막 질환 환자를 대상으로 하여 17명에게 bevacizumab 1.25 mg을, 11명에게 ranibizumab 0.5 mg을 유리체내로 주입하였다. 주입 직전과 주입 후 1일, 1주, 1달에 혈액 샘플을 채취하여 혈중 anti-vascular endothelial growth factor (anti-VEGF) 농도와 VEGF 농도를 enzyme-linked immunosorbent assay (ELISA) 방법으로 측정하였다. 결과: Bevacizumab 투여 전 anti-VEGF 농도는 91.0 ng/mL에서 1일, 1주, 1달 후 각각 153.6, 196.3, 140.3 ng/mL로 증가하였고(각각 p<0.05), VEGF 농도는 투여 전 93.9 pg/mL에서 1일, 1주, 1달 후 각각 40.1, 24.7, 33.5 pg/mL로 감소하였다(각각 p<0.05). Ranibizumab 투여 전 anti-VEGF 농도는 177.6 ng/mL에서 1일, 1주, 1달 후 각각 177.5, 160.7, 175.3 ng/mL로 유의한 변화가 없었고 (각각 p>0.05), VEGF 농도도 투여 전 80.9 pg/mL에서 1일, 1주, 1달 후 각각 96.7, 106.3, 106.1 pg/mL로 유의한 변화가 없었다(각각 p>0.05). 결론: Ranibizumab과 달리 bevacizumab은 유리체내 주입술 후 혈중 VEGF 농도를 유의하게 낮췄다. 따라서 유리체내 bevacizumab 주입술의 전신적인 영향에 대한 고려가 필요할 수 있다. Purpose: The purpose of this study was to evaluate the systemic effects of ranibizumab and bevacizumab by examining the plasma levels of anti-vascular endothelial growth factor (anti-VEGF) and VEGF before and after a single intravitreal injection. Methods: Twenty-eight eyes of 28 patients with various retinal diseases were enrolled. Seventeen eyes received an injection of intravitreal bevacizumab, and 11 eyes received an injection of ranibizumab. Blood samples were collected just before and 1 day, 1 week, and 1 month after injection. Concentrations of anti-VEGF and VEGF in plasma were measured using enzyme-linked immunosorbent assay (ELISA). Results: In the bevacizumab group, anti-VEGF concentration before the injection was 91.0 ng/mL, while those at 1 day, 1 week, and 1 month post-injection increased to 153.6, 196.3, and 140.3 ng/mL, respectively (p < 0.05 for all). VEGF concentration before the injection was 93.9 pg/mL, while those 1 day, 1 week, and 1 month post-injection were reduced to 40.1, 24.7, and 33.5 pg/mL, respectively (p < 0.05 for all). However, in the ranibizumab group, no significant reductions in anti-VEGF concentration were observed. The anti-VEGF concentration before the injection was 177.6 ng/mL, while those at 1 day, 1 week, and 1 month post-injection were 177.5, 160.7, 175.3 ng/mL, respectively (p > 0.05 for all). VEGF level also showed no significant change. VEGF concentration before the injection was 80.9 pg/mL, while those at 1 day, 1 week and 1 month post-injection were 96.7, 106.3, 106.1 pg/mL, respectively (p > 0.05 for all). Conclusions: Contrary to ranibizumab, intravitreal bevacizumab significantly lowers plasma VEGF level in patients with various retinal diseases. The study suggests the consideration of the systemic effects of intravitreal bevacizumab injection.

열공망막박리 유리체절제술 시 백내장수술 동시 시행 여부에 따른 재발 차이와 위험요인 분석

박혜인,윤명헌,진희승 대한안과학회 2017 대한안과학회지 Vol.58 No.12

Purpose: To compare the recurrence percentage and risk factors of recurrence in rhegmatogenous retinal detachment (RRD) after pars plana vitrectomy (PPV) by in two groups of patients according to combined cataract surgery. Methods: The recurrence percentage of RRD and risk factors after PPV over 20 years, performed by a single surgeon from January 1997 to September 2016, were retrospectively evaluated by classification into two groups according to combined cataract surgery. The risk factors were the patients' factors (age and sex), duration of disease, preoperative visual analyses, posterior capsular tears (PCR) during cataract surgery, the tamponade used, retinal detachment ranges, macular status, number and position of retinal tears, proliferative vitreoretinopathy (PVR) grade, and vitreous opacity. A total of 158 cases were included in the study. Results: The recurrence percentage of RRD was not associated with combined cataract surgery. In the combined cataract surgery group, PCR (p = 0.020), inferior retinal tears (p = 0.037), and PVR above grade B (p = 0.037) were associated with the recurrence of RRD using univariate logistic regression analyses, but PCR (odds ratio 1.880, p = 0.021) was the only significant risk factor for RRD using multivariate logistic regression analyses. Conclusions: Cataract surgery can be performed at any time, but there should be consideration of the recurrence of RRD if there was PCR during combined cataract surgery. 목적: 열공망막박리에서 유리체절제술 시 백내장수술 병행 여부에 따른 망막박리의 재발 빈도의 차이와 기존에 알려진 망막박리 재발의 위험요인을 분석해 보고자 한다. 대상과 방법: 1997년 1월부터 2016년 9월까지 20년에 걸쳐 내원 당시 처음으로 열공망막박리를 진단 받고 유리체절제술을 시행 받은 환자 중 진단 당시 유수정체안 158안을 대상으로, 유리체절제술과 동시에 본원에서 백내장수술을 받은 환자군과 그렇지 않은 환자군으로 나누어 이들의 의무기록을 후향적으로 분석하였다. 결과: 유리체절제술과 동시에 백내장수술을 받은 군과 받지 않은 군 간 비교에서는 백내장수술을 병행한 군이 평균 나이가 더 많았고(p=0.002) 두 군 간 망막박리 재발률은 유의한 차이를 보이지 않았다. 백내장수술을 받은 군에서 망막박리 재발의 위험 요인으로는, 단변량 분석에서 백내장수술 중 후낭파열이 있었던 경우(p=0.020), 아래쪽의 망막 열공(p=0.037), 증식성 유리체망막병증 grade B 이상(p=0.037)이었으나 다변량 분석에서는 백내장수술 중 후낭파열이 있는 경우에만 망막박리의 재발 위험이 높은 것으로 나타났다(odds ratio 1.880, p=0.021). 결론: 본 연구에서는 열공망막박리로 인한 유리제절제술 시 백내장수술 동시 시행 여부가 망막박리의 재발을 높인다는 근거를 발견하지 못했다. 백내장수술 동시 시행 여부는 여러 상황을 고려하여 탄력적으로 결정할 수 있으며, 백내장수술을 동시에 시행 시 후낭파열이 있었던 경우에 망막박리의 재발이 있는지를 추후 잘 살펴야 한다.

서로 다른 세가지 비구면 일체형 인공수정체 삽입 수술 후 임상 결과의 비교

이가현,윤명헌,서경률,김응권,김태임,Kahyun Lee,MD,Myung Hun Yoon,MD,Kyoung Yul Seo,MD,PhD,Eung Kweon Kim,MD,PhD,Tae-im Kim,MD,PhD 대한안과학회 2013 대한안과학회지 Vol.54 No.8

Purpose: To compare the clinical 3 months postoperative results of three different 1-piece aspheric intraocular lenses (IOLs): AcrySof IQ SN60WF (Alcon Laboratories, INC, Fort Worth, TX), TECNIS 1-piece ZCB00 (AMO Inc., Santa Ana, CA) and the newly developed enVista MX60 (Bausch & Lomb, Rochester, NY). Methods: In a total of 62 eyes, 1 of the 3 1-piece aspheric IOLs, AcrySof IQ SN60WF, TECNIS 1-piece ZCB00 or enVista MX60 was implanted after cataract extraction. Best corrected visual acuity (BCVA), uncorrected visual acuity (UCVA), and spherical equivalent were assessed 3 months postoperatively. Total spherical aberration, high order aberration, and modulation transfer function were analyzed. Results: There were no significant differences of UCVA, BCVA, the accuracy of postoperative refractive power, and modulation transfer function among the 3 IOLs. Higher order aberrations of the entire eye and internal optics showed almost no significant differences. Conclusions: The newly developed IOL, enVista MX60, showed equivalent clinical outcomes as both AcrySof IQ SN60WF and TECNIS 1-piece ZCB00.